* Note: Prices are in Million (M) USD.
Description:
Zymeworks Inc. is a Vancouver-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative biotherapeutics for cancer treatment. Its proprietary platforms enable the development of a diverse pipeline of product candidates, including a range of antibody-drug conjugates and bispecific therapeutics. With a commitment to advancing targeted therapies, Zymeworks aims to address unmet medical needs in oncology, positioning itself as a key player in the biopharmaceutical industry. The company's strategic collaborations and robust R&D capabilities further enhance its potential to deliver transformational treatments to patients.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $98 M
Debt : $7 M
EBITDA : $-61 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 11 overlapping fiscal years (max 20).Average Free Cash Flow: $-56 M
Average Revenue: $72 M
Revenue Converted To Free Cash Flow (%): -78.4%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $76 M
Revenue 5 Years Ago (2019-12-31): $30 M
Total Growth over 5 Years: 158.3%
5-Year Revenue CAGR (Historical): 20.9%
Forward 5-Year CAGR (Tapered): 14.6%
Since historical Revenue CAGR is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $76 M
Share Count 5 Years Ago (2020-12-31): $50 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-1.44
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-1.44
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 9 valid ROE years (max 20).Average ROE: -76.4%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $16.69
52-Week Low: $9.03
Threshold Price (15% Above 52-Week Low): $10.38
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $1,264 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2022-12-31): $1.73
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 11 points to above Zymeworks Inc. Common Stock (ZYME) stock.
Fair Value PE 12, Industry Based PE 15, Growth Based PE 15, Risk-Free Anchored PE (25% MoS) 18.2. Based on these 4 values, average assigned is 15.05. The fair value of Zymeworks Inc. Common Stock (ZYME) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
